Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Pharmacol ; 62(1): 110-8, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12065761

ABSTRACT

It is established that N(G)-amino-L-arginine (NAA) is a metabolism-based inactivator of all three major nitric-oxide synthase (NOS) isoforms. The mechanism by which this inactivation occurs, however, is not well understood. In the current study, we discovered that inactivation of the neuronal isoform of NOS (nNOS) by NAA in vitro results in covalent alteration of the heme prosthetic group, in part, to products that contain an intact porphyrin ring and are either dissociable from or irreversibly bound to the protein. The alteration of the heme is concomitant with the loss of nNOS activity. Studies with nNOS containing a 14C-labeled prosthetic heme moiety indicate that the major dissociable product and the irreversibly bound heme adduct account for 21 and 28%, respectively, of the heme that is altered. Mass spectral analysis of the major dissociable product gave a molecular ion of m/z 775.3 that is consistent with the mass of an adduct of heme and NAA minus a hydrazine group. Peptide mapping of the irreversibly bound heme adduct indicates that the heme is bound to a residue in the oxygenase domain of nNOS. We show for the first time that metabolism-based inactivation of nNOS occurs in vivo as highly similar heme products are formed. Because inactivation and alteration may trigger ubiquitination and proteasomal degradation of nNOS, NAA may be a useful biochemical tool for the study of these basic regulatory processes.


Subject(s)
Arginine/analogs & derivatives , Arginine/pharmacology , Enzyme Inhibitors/pharmacology , Heme/metabolism , Nitric Oxide Synthase/antagonists & inhibitors , Animals , Cells, Cultured , Heme/analysis , Humans , Insecta , Nitric Oxide Synthase/genetics , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type I , Rats , Transfection
2.
Hum Gene Ther ; 13(4): 543-51, 2002 Mar 01.
Article in English | MEDLINE | ID: mdl-11874632

ABSTRACT

Ganciclovir (GCV) is widely used as a prodrug for selective activation in tumor cells expressing herpes simplex virus thymidine kinase (HSV-TK) because of its ability to induce multi-log cytotoxicity to HSV-TK-expressing as well as nonexpressing bystander cells. We now report that another substrate for HSV-TK, D-carbocyclic 2'-deoxyguanosine (CdG), induces multi-log cytotoxicity in HSV-TK-expressing and bystander cells at concentrations

Subject(s)
Antiviral Agents/pharmacology , Deoxyguanosine/analogs & derivatives , Deoxyguanosine/pharmacology , Ganciclovir/pharmacology , Prodrugs/pharmacology , Thymidine Kinase/biosynthesis , Viral Proteins/biosynthesis , Antiviral Agents/metabolism , Antiviral Agents/therapeutic use , Cell Death/drug effects , Cell Death/genetics , Colonic Neoplasms/drug therapy , Colonic Neoplasms/genetics , Colonic Neoplasms/virology , Deoxyguanosine/metabolism , Deoxyguanosine/therapeutic use , Enzyme Activation/drug effects , Ganciclovir/metabolism , Ganciclovir/therapeutic use , Gene Transfer Techniques , Glioblastoma/drug therapy , Glioblastoma/genetics , Glioblastoma/virology , Prodrugs/metabolism , Prodrugs/therapeutic use , Simplexvirus/enzymology , Thymidine Kinase/genetics , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...